HPV infections and cytologic abnormalities in vaccinated women 21–34 years of age: Results from the baseline phase of the Onclarity trial

Parvu, Valentin; Stoler, Mark H.; Kodsi, Salma; Eckert, Karen; Yanson, Karen; Cooper, Charles K.

doi:10.1016/j.ygyno.2019.02.016

Cited by 17 publications

(13 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Additional limitations include the relatively low vaccination rate (11.3% in ASC-US and 15.5% in LSIL) and the fact this analysis does not take into account the number of prior screens that the subjects had had. Although a larger number of vaccinated subjects would reduce the prevalence of vaccine targeted genotypes and of HPV 16/18 associated ≥CIN2, it would not be expected to change the actual risk hierarchy [28]. Similarly, although subjects with a history of multiple prior negative screens would be expected to have a lower prevalence of ≥CIN2, such a history would not be expected to change the risk hierarchy [29].…”

Section: Discussionmentioning

confidence: 99%

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology

Stoler

Parvu

Yanson

et al. 2019

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

• HPV genotyping stratifies risk of ≥CIN2 or ≥CIN3 in women ≥21 years with ASC-US or LSIL cytology. • Women with HPV 16 had the greatest risk of ≥CIN2 or ≥CIN3 which is followed by those with HPV 31 in most instances. • HPV genotypes such as 51, 35/39/68, and 56/59/66 have a lower risk of ≥CIN2 or ≥CIN3 and may not require colposcopy. • These results support the use of HPV genotyping in risk-based management algorithms for women with either ASC-US or LSIL

show abstract

Section: Discussionmentioning

confidence: 99%

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology

Stoler

Parvu

Yanson

et al. 2019

Gynecologic Oncology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Thus, in those who continue to be screened with cytology only, as the prevalence of high‐grade cervical abnormalities and the incidence of cervical cancer decline, the proportion of false‐positive findings is expected to increase significantly. There is emerging evidence on screening outcomes from other countries with higher vaccine uptake, 34‐36 and some preliminary data from the United States 37‐39 that show significant declines in cervical abnormalities in vaccinated populations, and which point to the likelihood that future recommendations for cervical cancer screening will need to incorporate HPV vaccination status.…”

Section: Introductionmentioning

confidence: 99%

Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society

Fontham

Wolf

Church

et al. 2020

CA A Cancer J Clinicians

669

546

View full text Add to dashboard Cite

The American Cancer Society (ACS) recommends that individuals with a cervix initiate cervical cancer screening at age 25 years and undergo primary human papillomavirus (HPV) testing every 5 years through age 65 years (preferred); if primary HPV testing is not available, then individuals aged 25 to 65 years should be screened with cotesting (HPV testing in combination with cytology) every 5 years or cytology alone every 3 years (acceptable) (strong recommendation). The ACS recommends that individuals aged >65 years who have no history of cervical intraepithelial neoplasia grade 2 or more severe disease within the past 25 years, and who have documented adequate negative prior screening in the prior 10 years, discontinue all cervical cancer screening (qualified recommendation). These new screening recommendations differ in 4 important respects compared with the 2012 recommendations: 1) The preferred screening strategy is primary HPV testing every 5 years, with cotesting and cytology alone acceptable where access to US Food and Drug Administration-approved primary HPV testing is not yet available; 2) the recommended age to start screening is 25 years rather than 21 years; 3) primary HPV testing, as well as cotesting or cytology alone when primary testing is not available, is recommended starting at age 25 years rather than age 30 years; and 4) the guideline is transitional, ie, options for screening with cotesting or cytology alone are provided but should be phased out once full access to primary HPV testing for cervical cancer screening is available without barriers. Evidence related to other relevant issues was reviewed, and no changes were made to recommendations for screening intervals, age or criteria for screening cessation, screening based on vaccination status, or screening after hysterectomy. Follow-up for individuals who screen positive for HPV and/or cytology should be in accordance with the 2019 American Society for Colposcopy and Cervical Pathology risk-based management consensus guidelines for abnormal cervical cancer screening tests and cancer precursors.

show abstract

“…HPV genotyping has been mostly focused on HPV16 and HPV18 due to their high prevalence in cervical cancer, although, other hr-types indicate high positive predictive value (PPV) [8,10]. Earlier studies suggested that extended HPV genotyping provides a better risk stratification and identification of women at increased risk of cervical cancer by simply providing individual risk assessment of HPV positive women [33][34][35].…”

Section: Discussionmentioning

confidence: 99%

“…HPV oncogenic potential is highly type-dependent as some types are more oncogenic. Many studies have shown that extended genotyping information holds important clinical value for patient management and triage of HPV positive women [8][9][10].…”

Section: Introductionmentioning

confidence: 99%

A Comprehensive HPV-STI NGS Assay for Detection of 29 HPV Types and 14 non-HPV Sexually Transmitted Infections

Ma¹,

Gharizadeh²,

Cai

et al. 2021

Preprint

View full text Add to dashboard Cite

Sexually transmitted infections (STIs) are prevalent throughout the world and impose a significant burden on individual health and public health systems. Missed diagnosis and late treatment of STIs can lead to serious complications such as infertility and cervical cancer. Although sexually transmitted co-infections are common, most commercial assays target one or a few STIs. The HPV-STI ChapterDx Next Generation Sequencing (NGS) assay detects and quantifies 29 HPVs and 14 other STIs in a single-tube and single-step PCR reaction and can be applied to tens to thousands of samples in a single sequencing run. The assay was evaluated in this study, and the limit of detection was 100% at 50 copies for all targets, and 100%, 96%, 88% at 20 copies for 34, 8, and 1 target, respectively. The performance of this assay has been compared to Roche cobas HPV test, showing an overall agreement of 97.5% for hr-HPV, and 98.5% for both, HPV16 and HPV18. The assay also detected all HPV-infected CIN2/3 with 100% agreement with Roche cobas HPV results. Moreover, several co-infections with non-HPV STIs, such as C. trachomatis, T. vaginalis, M. genitalium, and HSV2 were identified. The ChapterDx HPV-STI NGS assay is a user-friendly, easy to automate and cost-efficient assay, which provides accurate and comprehensive results for a wide spectrum of HPVs and STIs.

show abstract

HPV infections and cytologic abnormalities in vaccinated women 21–34 years of age: Results from the baseline phase of the Onclarity trial

Cited by 17 publications

References 36 publications

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology

Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society

A Comprehensive HPV-STI NGS Assay for Detection of 29 HPV Types and 14 non-HPV Sexually Transmitted Infections

Contact Info

Product

Resources

About

HPV infections and cytologic abnormalities in vaccinated women 21–34 years of age: Results from the baseline phase of the Onclarity trial

Cited by 17 publications

References 36 publications

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology

Cervical cancer screening for individuals at average risk: 2020 guideline update from the American Cancer Society

A Comprehensive HPV-STI NGS Assay for Detection of 29 HPV Types and 14 non-HPV Sexually Transmitted Infections

Contact Info

Product

Resources

About

HPV infections and cytologic abnormalities in vaccinated women 21–34 years of age: Results from the baseline phase of the Onclarity trial

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology

Risk detection for high-grade cervical disease using Onclarity HPV extended genotyping in women, ≥21 years of age, with ASC-US or LSIL cytology